BioSpace News Archive

AbbVie, a global, research-based biopharmaceutical company, and MBC BioLabs announced today that Bacchus Therapeutics and PTM Therapeutics have each won a 2020 AbbVie Golden Ticket at MBC BioLabs. The co

Vasoptic Medical Inc., a Maryland -based medical device company, announced today that the company received 510(k) clearance from the U.S. Food & Drug Administration to market its XyCAM RI™—a non-invasive retinal imager designed to capture and provide dynamic blood flow information for clinical use. The XyCAM RI can allow ophthalmologis

ICAN, a regional leader in pediatric rehabilitative therapy, is launching a new Statewide Telehealth initiative, ICANational. ICAN’s history of a comprehensive and innovative clinic experience providing speech, occupational and physical therapy will now be accessible to every child in Washington State , due to this pioneering telehea

The Accreditation Council for Medical Affairs (ACMA) today announced its new head of business for Asia, Yue Hu.

MIVI Neuroscience, a leading developer, and marketer of precision stroke therapy devices utilized by neurointerventionists around the world, announced today that the FDA has determined the company has provided sufficient data to support initiation of a human clinical study of the MIVI Q Aspiration Catheter in the United States. T

Melinta Therapeutics, Inc. (“Melinta”), a commercial-stage antibiotics company, announced that on June 4, 2020, it entered into a definitive merger agreement with Tetraphase Pharmaceuticals, Inc. (“Tetraphase”) pursuant to which Melinta would acquire Tetraphase,

Healthpeak Properties, Inc. (NYSE: PEAK) announced today that it has priced a public offering of $600 million aggregate principal amount of 2.875% senior unsecured notes due 2031

Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (“BBB”) for neurodegenerative diseases, today announced the results from its Phase 1b studies with small molecule RIPK1 inhibitor DNL747 in Alzheimer’s disease and ALS, and provided a broad RIPK1 program update including DNL788 and DNL758.

Legend Biotech (NASDAQ: LEGN) announced today that it has appointed Dr. Corazon (Corsee) Dating Sanders, Dr. Darren Ji, and Mr. Philip Yau to the company’s Board of Directors

Dr. Kia Motesharei joins from Merck KGaA, bringing more than 20 years of experience in the pharmaceutical and biotechnology industry [09-June-2020] BOSTON , June 9, 2020 /PRNewswire/ -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced that Kia Motesharei , Ph.D., has joined the company as Senior Vice